Table 4 Laboratory findings and disease activity of SLE patients with and without APS
Total (n = 103) | SLE (n = 75) | SLE + APS (n = 28) | P-value | |
|---|---|---|---|---|
Positive aCL-IgM | 16 (15.5) | 4 (5.3) | 12 (42.9) | < 0.001** |
Positive aCL-IgG | 6 (5.8) | 1 (1.3) | 5 (17.9) | 0.005* |
Positive anti-B2GP-IgM | 5 (4.9) | 0 (0.0) | 5 (17.9) | 0.001* |
Positive anti-B2GP-IgG | 7 (6.8) | 2 (2.7) | 5 (17.9) | 0.006* |
Positive LA | 20 (19.4) | 2 (2.7) | 18 (64.3) | < 0.001** |
Positive ANA | 102 (99.0) | 74 (98.7) | 28 (100.0) | 1.0 |
Positive anti-dsDNA | 67 (65.0) | 46 (61.3) | 21 (75.0) | 0.196 |
Positive anti-RO | 5 (4.9) | 0 (0.0) | 5 (17.9) | < 0.001** |
Positive anti-LA | 2 (1.9) | 0 (0.0) | 2 (7.1) | 0.072 |
Positive anti-SMITH | 5 (4.9) | 3 (4.0) | 2 (7.1) | 0.611 |
Positive anti-U1RNP | 3 (2.9) | 1 (1.3) | 2 (7.1) | 0.179 |
C3 | ||||
Normal | 37 (35.9) | 27 (36.0) | 10 (35.7) | 0.979 |
Low | 66 (64.1) | 48 (64.0) | 18 (64.3) | |
C4 | ||||
Normal | 37 (35.9) | 27 (36.0) | 10 (35.7) | 0.979 |
Low | 66 (64.1) | 48 (64.0) | 18 (64.3) | |
TC (mg/dl) | 85.4 ± 21.7 | 82.3 ± 19.6 | 93.8 ± 25.3 | 0.018* |
TG (mg/dl) | 20.7 (7–65.7) | 20 (7–65.7) | 28.8 (8.1–47.2) | 0.126 |
LDL (mg/dl) | 52.1 ± 17.4 | 50 ± 15.9 | 57.7 ± 20.3 | 0.048* |
HDL (mg/dl) | 23.7 ± 8.1 | 23.4 ± 7.8 | 24.6 ± 8.9 | 0.514 |
SLEDAI | 12 (4–29) | 11 (4–29) | 17 (6–29) | < 0.001* |